ClinicalTrials.gg
CompletedNCT00440557Updated May 7, 2014Results posted

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

A Phase 3 interventional study of Epoetin alfa 3 times weekly /once weekly and Epoetin alfa once weekly in Anemia, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 62 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-07.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.

Enrollment
9th of 112
375 · median 71
Started
2006
with 7 others
Phase 3
45 of 126
1 open now
Registered
89th of 126
by date
Lead sponsor
53 of 126
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 9th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2006, is one of 45 in phase 3, and was the 89th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing Epoetin Alfa in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate that once weekly and once every-2-weeks treatment with epoetin alfa, in patients with anemia associated with chronic kidney disease, is not less effective than the approved treatment with epoetin alfa that is given 3 times weekly with respect to changes in hemoglobin.

Read the detailed description

This is a open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), multicenter study designed to show that 2 alternative dosing regimens, once weekly and once every-2-weeks (given at doses equivalent to 50 IU/kg 3 times a week) are not inferior to the 3-times-weekly dosing regimen. Approximately 375 patients with anemia will be enrolled in this study. Patients will be randomly assigned to receive epoetin alfa by subcutaneous (SC) injection according to one of the following 3 regimens: 3 times weekly (Group 1), once weekly (Group 2), or once every 2 weeks (Group 3) for 22 weeks. Thereafter, patients in Group 1 will be switched to the once-weekly dosing regimen for an additional 22 weeks, and patients in Groups 2 and 3 will continue their current treatment for an additional 22 weeks. The total duration of the open-label treatment phase is 44 weeks which will include initiation and maintenance treatment periods (with the goal of increasing, then maintaining, the hemoglobin level between 11.0 and 11.9 g/dL inclusive) and a safety period (to assess longer exposure to epoetin alfa treatment and any period of hemoglobin instability during the transition from 3-times-weekly to once-weekly dosing). Starting doses of epoetin alfa in the 3-times-weekly, once-weekly, and every-2-weeks groups will be 50 IU/kg, 10,000 IU, and 20,000 IU, respectively; thereafter adjusted according to weekly hemoglobin concentrations. Safety evaluations will include assessment of adverse events, laboratory tests, physical examinations, and vital signs.

03

Conditions studied

  • Anemia

Keywords

  • Anemia
  • Chronic Kidney disease
  • Kidney disease
  • Epoetin alfa
  • Procrit
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria for chronic kidney disease, defined as a (GFR) more than or equal to 15 mL/min per 1.73 m2 and less than 60 mL/min per 1.73 m2 (Stages 3 and 4) as calculated by the central laboratory
  • Require support of an erythropoietin receptor agonist

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension
  • Serum ferritin level less than 50 ng/mL
  • Serum iron overload
  • Severe congestive heart failure
  • Active infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    TIW: Epoetin alfa 3 injections Weekly/Once Weekly

    Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)

    Drug: Epoetin alfa 3 times weekly /once weekly

  • Experimental
    QW: Epoetin alfa once weekly

    Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).

    Drug: Epoetin alfa once weekly

  • Experimental
    Q2W: Epoetin alfa once every two weeks

    Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).

    Drug: Epoetin alfa once every two weeks

Interventions

  • DrugEpoetin alfa 3 times weekly /once weekly

    Drug page: Epoetin Alfa

    Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)

    Also known as: PROCRIT

  • Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).

    Also known as: PROCRIT

  • Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).

    Also known as: PROCRIT

06

What researchers measure

Primary outcomes

  1. Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22

    The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included in calculating the average Hb during the last 8 weeks of treatment through Week 22.

    Time frame: From baseline through Week 22

Secondary outcomes

  1. Participants With an Increase of ≥1 g/dL in Hb Concentration From Baseline by Week 9

    The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Hb increase is defined as the post-baseline Hb level minus the baseline Hb level.

    Time frame: From baseline to Week 9

Other outcomes

  1. Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment

    The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. participants who exceed a Hb value of 11.9 g/dL at least once were included in the numerator of the percentage calculation.

    Time frame: From baseline to Week 22

  2. Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment

    The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. A maximum Hb observation was identified for each participant during the first 22 weeks of treatment.

    Time frame: From baseline to Week 22

  3. Participants Who Met or Exceeded Hb Rate of Rise >=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment

    Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.

    Time frame: From baseline to Week 22

  4. Participants Who Met or Exceeded Hb Rate of Rise >=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment

    Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.5 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.

    Time frame: From baseline to Week 22

  5. Particpants Who Met or Exceeded Hb Rate of Rise >=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment

    Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 2.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.

    Time frame: From baseline to Week 22

07

Results

Posted Feb 8, 2010

Participant flow

The study was initiated 29 August 2006 and completed on 21 February 2008. Subjects were screened for eligibility at 64 investigative sites within the U.S. Three hundred seventy-five subjects (intent to treat) were randomly assigned to a treatment group by 52 investigators from 56 sites. Safety population consisted of 373 subjects.

Participant flow — Overall Study
MilestoneEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Started123125125
Completed989690
Not completed252935
Withdrew: Withdrawal by subject10511
Withdrew: Lost to follow-up126
Withdrew: Adverse event335
Withdrew: Death263
Withdrew: Began dialysis414
Withdrew: Principal investigator decision031
Withdrew: Patient moved121
Withdrew: Principal investigator's office closed364
Withdrew: Patient transferred to nursing home010
Withdrew: Patient had surgery100

Outcome measures

PrimaryChange in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22

The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included in calculating the average Hb during the last 8 weeks of treatment through Week 22.

Time frame:
From baseline through Week 22
Reported as:
Mean · g/dL
Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22
g/dLEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 221.81 ± 0.9101.59 ± 0.9971.27 ± 0.906
Statistical analysis
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Weekly (QW) · Difference of least squares means: -0.17 · 95% CI -0.380 to 0.037
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Every Two Weeks (Q2W) · Difference of least squares means: -0.43 · 95% CI -0.641 to -0.221
Other pre-specifiedParticipants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment

The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. participants who exceed a Hb value of 11.9 g/dL at least once were included in the numerator of the percentage calculation.

Time frame:
From baseline to Week 22
Reported as:
Number · participants
Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment
participantsEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment1069889
Statistical analysis
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Weekly (QW) · Difference in percentage of participants: -7.8 · 95% CI -17.2 to 1.7
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Every Two Weeks (Q2W) · Difference in percentage of participants: -15.0 · 95% CI -25.0 to -5.0
Other pre-specifiedMaximum Hb Concentration (g/dL) During First 22 Weeks of Treatment

The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. A maximum Hb observation was identified for each participant during the first 22 weeks of treatment.

Time frame:
From baseline to Week 22
Reported as:
Mean · g/dL
Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment
g/dLEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment12.87 ± 1.17612.61 ± 1.15812.42 ± 1.310
Statistical analysis
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Weekly (QW) · ANOVA · Difference of least squares means: -0.26 · 95% CI -0.564 to 0.043
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Every Two Weeks (Q2W) · ANOVA · Difference of least squares means: -0.45 · 95% CI -0.755 to -0.147
Other pre-specifiedParticipants Who Met or Exceeded Hb Rate of Rise >=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment

Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.

Time frame:
From baseline to Week 22
Reported as:
Number · participants
Participants Who Met or Exceeded Hb Rate of Rise >=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment
participantsEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Participants Who Met or Exceeded Hb Rate of Rise >=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment119116114
Statistical analysis
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Weekly (QW) · Difference in percentage of participants: -3.9 · 95% CI -9.5 to 1.6
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Every Two Weeks (Q2W) · Difference in percentage of participants: -5.5 · 95% CI -11.4 to 0.3
Other pre-specifiedParticipants Who Met or Exceeded Hb Rate of Rise >=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment

Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.5 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.

Time frame:
From baseline to Week 22
Reported as:
Number · participants
Participants Who Met or Exceeded Hb Rate of Rise >=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment
participantsEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Participants Who Met or Exceeded Hb Rate of Rise >=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment878576
Statistical analysis
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Weekly (QW) · Difference in percentage of participants: -2.7 · 95% CI -14.2 to 8.7
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Every Two Weeks (Q2W) · Difference in percentage of participants: -9.9 · 95% CI -21.7 to 1.8
Other pre-specifiedParticpants Who Met or Exceeded Hb Rate of Rise >=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment

Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 2.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.

Time frame:
From baseline to Week 22
Reported as:
Number · participants
Particpants Who Met or Exceeded Hb Rate of Rise >=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment
participantsEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Particpants Who Met or Exceeded Hb Rate of Rise >=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment475144
Statistical analysis
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Weekly (QW) · Difference in percentage of participants: 2.6 · 95% CI -9.6 to 14.8
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Every Two Weeks (Q2W) · Difference in percentage of participants: -3.0 · 95% CI -15.0 to 9.0
Post-hocMaximum (Max) Hb Rate (g/dL/2 Weeks) of Rise During First 22 Weeks of Treatment

Change is calculated as mean hemoglobin (Hb) over last 8 wks subtracts baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Max Hb RR observation was identified for each participant during the 1st 22 wks of treatment. This was the max RR in hemoglobin over any 2-wk period per participant.

Time frame:
From baseline to Week 22
Reported as:
Mean · g/dL/2 weeks
Maximum (Max) Hb Rate (g/dL/2 Weeks) of Rise During First 22 Weeks of Treatment
g/dL/2 weeksEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Maximum (Max) Hb Rate (g/dL/2 Weeks) of Rise During First 22 Weeks of Treatment1.99 ± 0.8392.02 ± 1.0081.92 ± 1.027
Statistical analysis
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Weekly (QW) · ANOVA · Difference of least squares means: 0.03 · 95% CI -0.210 to 0.270
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Every Two Weeks (Q2W) · ANOVA · Difference of least squares means: -0.07 · 95% CI -0.315 to 0.166
SecondaryParticipants With an Increase of ≥1 g/dL in Hb Concentration From Baseline by Week 9

The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Hb increase is defined as the post-baseline Hb level minus the baseline Hb level.

Time frame:
From baseline to Week 9
Reported as:
Number · participants
Participants With an Increase of ≥1 g/dL in Hb Concentration From Baseline by Week 9
participantsEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Participants With an Increase of ≥1 g/dL in Hb Concentration From Baseline by Week 9116108106
Statistical analysis
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Weekly (QW) · Difference in percentage of participants: -8.8 · 95% CI -16 to -1.9
  • Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW) vs Epoetin Alfa:Once Every Two Weeks (Q2W) · Difference in percentage of participants: -10.0 · 95% CI -18.0 to -3.2

Adverse events

Collected over 44 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)—36/123 (29.3%)93/123 (75.6%)
Epoetin Alfa:Once Weekly (QW)—41/125 (32.8%)85/125 (68%)
Epoetin Alfa:Once Every Two Weeks (Q2W)—42/125 (33.6%)102/125 (81.6%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
Cardiac failure congestiveCardiac disorders4/1234/1256/125
HypoglycaemiaMetabolism and nutrition disorders5/1234/1250/125
Myocardial InfarctionCardiac disorders0/1232/1255/125
Renal failure chronicRenal and urinary disorders4/1233/1255/125
Renal failure acuteRenal and urinary disorders2/1232/1253/125
Gastrointestinal haemorrhageGastrointestinal disorders1/1231/1253/125
Hip fractureInjury, poisoning and procedural complications1/1231/1253/125
FallInjury, poisoning and procedural complications0/1230/1253/125
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1230/1253/125
PneumoniaInfections and infestations2/1232/1252/125
Most frequent other events
Showing 10 of 23
Most frequent other events
EventEpoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)
HypertensionVascular disorders15/12318/12510/125
DizzinessNervous system disorders12/1237/12516/125
Oedema peripheralGeneral disorders15/1237/12512/125
HyperkalaemiaMetabolism and nutrition disorders15/12310/12514/125
HeadacheNervous system disorders15/1239/1253/125
Urinary tract infectionInfections and infestations9/12315/12514/125
ConstipationGastrointestinal disorders8/1233/12514/125
DiarrhoeaGastrointestinal disorders13/12313/12510/125
NauseaGastrointestinal disorders13/1239/1259/125
FatigueGeneral disorders13/1239/12512/125

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)Total
<=18 years0000
Between 18 and 65 years334344120
>=65 years908281253
Age, Continuous
Age, Continuous(years)Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)Total
Mean71.1 ± 13.0268.9 ± 11.8668.9 ± 13.0269.6 ± 12.65
Sex: Female, Male
Sex: Female, Male(Participants)Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)Epoetin Alfa:Once Weekly (QW)Epoetin Alfa:Once Every Two Weeks (Q2W)Total
Female778085242
Male464540131
08

Study locations

62 sites
  • Glendale, Arizona, United States
  • Tempe, Arizona, United States
  • Chula Vista, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Lynwood, California, United States
  • Riverside, California, United States
  • San Diego, California, United States
  • Visalia, California, United States
  • Whittier, California, United States
  • Yuba City, California, United States
  • Colorado Springs, Colorado, United States
  • Lakewood, Colorado, United States
  • Thornton, Colorado, United States
  • Lauderdale Lakes, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Palm Beach Gardens, Florida, United States
  • Tampa, Florida, United States
  • West Palm Beach, Florida, United States
  • Zephyrhills, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Carrollton, Georgia, United States
  • Macon, Georgia, United States
  • Statesboro, Georgia, United States
  • Chicago, Illinois, United States
  • Peoria, Illinois, United States
  • Baltimore, Maryland, United States
  • Bethesda, Maryland, United States
  • Methuen, Massachusetts, United States
  • Plymouth, Massachusetts, United States
  • Flint, Michigan, United States
  • Hackensack, New Jersey, United States
  • Old Bridge, New Jersey, United States
  • Vineland, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Great Neck, New York, United States
  • New Hartford, New York, United States
  • New York, New York, United States
  • Springfield Gardens, New York, United States
  • Charlotte, North Carolina, United States
  • Greenville, North Carolina, United States
  • Maumee, Ohio, United States
  • Doylestown, Pennsylvania, United States
  • Easton, Pennsylvania, United States
  • Erie, Pennsylvania, United States
  • Lancaster, Pennsylvania, United States
  • Wynnewood, Pennsylvania, United States
  • Bamberg, South Carolina, United States
  • Orangeburg, South Carolina, United States
  • Sumter, South Carolina, United States
  • Dyersburg, Tennessee, United States
  • Arlington, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Chesapeake, Virginia, United States
  • Fairfax, Virginia, United States
  • Hampton, Virginia, United States
  • Richmond, Virginia, United States
  • Tacoma, Washington, United States
  • Caguas, Puerto Rico
09

References and documents

Publications

  • Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia. Clin J Am Soc Nephrol. 2009 Nov;4(11):1731-40. doi: 10.2215/CJN.03470509. Epub 2009 Sep 17. PubMed 19808215 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2007
First posted
Feb 27, 2007
Start
Sep 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Feb 8, 2010
Last update
May 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00440557
Responsible party
Sponsor
First posted
Feb 27, 2007
Start date
Sep 2006
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Feb 8, 2010
Last update
May 7, 2014

Study contacts

Johnson & Johnson Pharmaceutical Research and Development, L.L C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion